series-c-plus
Stage
1
Investors
About
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors to treat diseases associated with fatty acid overproduction, including acne, metabolic dysfunction-associated steatohepatitis (MASH), and certain FASN-dependent tumors.
Explore Sagimet's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.